BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up [Yahoo! Finance]
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? [Yahoo! Finance]
Summit boosts Instil, BioNTech as lead drug beats Merck's Keytruda [Seeking Alpha]